

Marina E Cazzaniga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8022104/publications.pdf>

Version: 2024-02-01

78
papers

3,984
citations

172207

29
h-index

118652

62
g-index

79
all docs

79
docs citations

79
times ranked

4792
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology</i> , The, 2015, 16, 1306-1315.	5.1	835
2	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 362-372.	3.0	768
3	Elaeestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	0.8	190
4	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	2.0	179
5	Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. <i>British Journal of Cancer</i> , 1995, 71, 854-856.	2.9	130
6	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 392-398.	0.9	116
7	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	2.0	86
8	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014, 25, 1373-1378.	0.6	84
9	Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120.	0.9	73
10	A Randomized Study of Low-Dose Subcutaneous Interleukin-2 Plus Melatonin versus Supportive Care Alone in Metastatic Colorectal Cancer Patients Progressing under 5-Fluorouracil and Folates. <i>Oncology</i> , 1995, 52, 243-245.	0.9	70
11	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3116-3122.	0.6	69
12	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 299-306.	1.4	67
13	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	5.1	59
14	Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. <i>British Journal of Cancer</i> , 1993, 67, 1404-1407.	2.9	52
15	Breast cancer in elderly women: a different reality? Results from the NORA study. <i>Annals of Oncology</i> , 2007, 18, 991-996.	0.6	51
16	Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). <i>Quality of Life Research</i> , 2017, 26, 2999-3010.	1.5	51
17	Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 501-509.	1.1	49
18	Reversal of Clinical Resistance to LHRH Analogue in Metastatic Prostate Cancer by the Pineal Hormone Melatonin: Efficacy of LHRH Analogue plus Melatonin in Patients Progressing on LHRH Analogue Alone. <i>European Urology</i> , 1997, 31, 178-181.	0.9	47

#	ARTICLE	IF	CITATIONS
19	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. <i>Future Oncology</i> , 2016, 12, 373-387.	1.1	43
20	Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study. <i>International Journal of Breast Cancer</i> , 2014, 2014, 1-7.	0.6	42
21	Efficacy of the Concomitant Administration of the Pineal Hormone Melatonin in Cancer Immunotherapy with Low-Dose IL-2 in Patients with Advanced Solid Tumors Who Had Progressed on IL-2 Alone. <i>Oncology</i> , 1994, 51, 344-347.	0.9	40
22	Venous thromboembolism and cancer: new issues for an old topic. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 65-80.	2.0	38
23	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	1.3	38
24	Methotrexate inhibits SARS-CoV-2 virus replication <i>in vitro</i> . <i>Journal of Medical Virology</i> , 2021, 93, 1780-1785.	2.5	38
25	Metronomic Chemotherapy. <i>Cancers</i> , 2021, 13, 2236.	1.7	38
26	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
27	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. <i>Breast</i> , 2019, 48, 7-16.	0.9	37
28	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. <i>Supportive Care in Cancer</i> , 2004, 12, 446-453.	1.0	34
29	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 15-23.	1.4	34
30	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: <i>post hoc</i> analysis of a prospective study. <i>European Journal of Neurology</i> , 2013, 20, 788-794.	1.7	30
31	Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 1997, 5, 314-317.	1.0	29
32	Metronomic chemotherapy for advanced breast cancer patients. <i>Cancer Letters</i> , 2017, 400, 252-258.	3.2	29
33	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 483-494.	1.1	28
34	Biological Characteristics and Medical Treatment of Breast Cancer in Young Women: A Featured Population: Results from the NORA Study. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-6.	0.6	27
35	A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. <i>Supportive Care in Cancer</i> , 1995, 3, 194-197.	1.0	26
36	Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era. <i>Oncologist</i> , 2008, 13, 373-381.	1.9	26

#	ARTICLE	IF	CITATIONS
37	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018, 26, 3143-3151.	1.0	23
38	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2989-2997.	1.0	23
39	Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1662-1663.	0.5	22
40	Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2âˆ”) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. <i>Breast</i> , 2017, 35, 115-121.	0.9	21
41	Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. <i>Oncotarget</i> , 2018, 9, 27448-27459.	0.8	20
42	Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. <i>Advances in Therapy</i> , 2019, 36, 381-406.	1.3	19
43	Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. <i>Supportive Care in Cancer</i> , 2005, 13, 375-380.	1.0	18
44	Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. <i>Annals of Oncology</i> , 2009, 20, 655-659.	0.6	18
45	Prediction of Recurrence in Operable Breast Cancer by Postoperative Changes in Prolactin Secretion. <i>Oncology</i> , 1995, 52, 439-442.	0.9	17
46	Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. <i>European Journal of Cancer</i> , 1997, 33, 304-306.	1.3	17
47	Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study. <i>Tumori</i> , 2017, 103, e4-e8.	0.6	17
48	Pharmacogenetic interaction analysis of <i>VEGFR-2</i> and <i>IL-8</i> polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. <i>Pharmacogenomics</i> , 2014, 15, 1985-1999.	0.6	16
49	Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study. <i>Oncology</i> , 2006, 71, 374-381.	0.9	14
50	Adjuvant systemic treatment of early breast cancer: the NORA study. <i>Annals of Oncology</i> , 2006, 17, 1386-1392.	0.6	14
51	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
52	Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?. <i>International Journal of Breast Cancer</i> , 2017, 2017, 1-6.	0.6	12
53	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , 2017, 22, 648-654.	1.9	10
54	Bisphosphonates and metastatic bone disease. <i>Annals of Oncology</i> , 2006, 17, ii91-ii95.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. <i>Annals of Oncology</i> , 2007, 18, 1976-1980.	0.6	9
56	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594.	1.1	9
57	Vinorelbine and Carboplatin in Inoperable Non-Small Cell Lung Cancer: A Monoinstitutional Phase II Study. <i>Oncology</i> , 2003, 64, 97-101.	0.9	8
58	Patterns of Relapse and Modalities of Treatment of Breast Cancer: The "IRIS" Project, a Multicenter Observational Study. <i>Oncology</i> , 2004, 66, 260-268.	0.9	8
59	From the trastuzumab era to new target therapies: beyond revolution. <i>Annals of Oncology</i> , 2007, 18, vi1-vi4.	0.6	8
60	How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. <i>Life</i> , 2022, 12, 378.	1.1	8
61	The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. <i>Thrombosis and Haemostasis</i> , 2006, 95, 752-754.	1.8	7
62	Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. <i>Clinical Breast Cancer</i> , 2017, 17, 433-440.	1.1	6
63	Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 415-424.	1.1	6
64	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634.	0.7	4
65	Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?. <i>Colorectal Disease</i> , 2004, 6, 129-130.	0.7	3
66	Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project. <i>Clinical Breast Cancer</i> , 2021, 21, e547-e560.	1.1	3
67	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 103-109.	1.1	3
68	Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. <i>Tumori</i> , 2013, 99, 596-600.	0.6	2
69	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	1.1	1
70	Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 805-814.	1.1	1
71	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 301-318.	1.1	1
72	Is metronomic vinorelbine (mVRL) able to inhibit both HUVEC and triple-negative breast cancer (TNBC) cells? The proof-of-concept VICTOR-0 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14014-e14014.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Acute dyspnea due to right phrenic palsy during infusional chemotherapy. <i>Annals of Oncology</i> , 2004, 15, 691-692.	0.6	0
74	The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study. <i>Annals of Oncology</i> , 2008, 19, 1811-1812.	0.6	0
75	In reply to Kadri Altundag. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 387-387.	1.1	0
76	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	0.8	0
77	The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1389-1392.	1.1	0
78	Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL. <i>Cancer Research</i> , 2022, 82, OT2-19-06-OT2-19-06.	0.4	0